Form 4: BioAtla CEO's RSU Tax Withholding Reported

BioAtla CEO Jay M. Short's recent Form 4 filing details the withholding of 7,728 common shares by the issuer to cover tax obligations related to vested restricted stock units.

Summary

• CEO Jay M. Short reported a transaction involving BioAtla, Inc. common stock.
• 7,728 shares were disposed of on February 28, 2026, at a price of $0.247 per share.
• This transaction represents shares withheld by BioAtla, Inc. to satisfy income tax and withholding obligations upon the vesting and net settlement of previously reported restricted stock units.
• This was not a sale of shares by Dr. Short.
• Following the transaction, Dr. Short directly owns 2,229,603 shares and indirectly owns 1,613,375 shares through various entities and trusts.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine tax withholding related to the vesting of executive equity compensation, indicating a milestone in the CEO's compensation plan and continued significant insider ownership.

Positives

• The transaction reflects the vesting of previously granted restricted stock units, indicating a milestone in executive compensation.
• CEO Jay M. Short maintains substantial direct and indirect beneficial ownership in BioAtla, Inc., totaling over 3.8 million shares, aligning his interests with shareholders.

Negatives

• 7,728 shares of common stock were withheld by the issuer, reducing the direct beneficial ownership of the CEO.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insiders. This specific transaction, a tax withholding for RSU vesting, is a common occurrence in executive compensation structures across the biotech industry, reflecting the realization of equity compensation.

Comparison to Industry Standards

• The mechanism of withholding shares for tax obligations upon RSU vesting is a standard practice in executive compensation plans across various industries, including biotechnology, aligning with common corporate governance practices for equity awards.

Related Party Transactions

• Indirect beneficial ownership includes shares held by the CEO's spouse, the Carolyn Short 2020 Irrevocable Gift Trust, the Jay Short 2020 Irrevocable Gift Trust, Capia IP, LLC, and Himalaya Parent LLC, where the CEO and spouse are managers.

Stakeholder Impact

• Shareholders: The CEO's continued substantial direct and indirect ownership aligns his interests with those of other shareholders.
• Employees: The vesting of RSUs is a common form of equity compensation, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding event related to the vesting of restricted stock units for the CEO. It does not indicate any fundamental change in the company's operations, financial health, or strategic direction that would warrant a change in investment recommendation. The CEO maintains significant beneficial ownership, which is generally a positive for shareholder alignment.

Keywords

BioAtla, BCAB, Form 4, insider transaction, CEO, stock ownership, restricted stock units, RSU, tax withholding, beneficial ownership